隶属于 city of hope national cancer institute
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1913
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- The BLAZE Phase 1/2 trial has updated its anti-PD-1 combination backbone to nivolumab (Opdivo®) and is advancing toward first patient enrollment in checkpoint-resistant NSCLC and melanoma. - The BEXAR randomized Phase 1b/2 trial received regulatory approval to evaluate bexmarilimab plus doxorubicin in first-line metastatic soft-tissue sarcoma, a tumor type with among the highest Clever-1 expression. - The proposed bexmarilimab cohort in the FINPROVE platform trial was deemed incompatible by Finnish regulators (Fimea) and will not proceed, though this does not affect the broader development program. - Two additional IITs in hematological malignancies — BEAM-X in MRD-positive AML and a City of Hope-sponsored trial in r/r MDS — continue advancing through protocol development.
- Delcath Systems has dosed the first patient in a Phase 2 clinical trial evaluating HEPZATO in combination with standard care for liver-dominant metastatic colorectal cancer at City of Hope National Medical Center. - The randomized, controlled trial will enroll approximately 90 patients across more than 20 sites in the United States and Europe, comparing HEPZATO plus trifluridine-tipiracil and bevacizumab against standard care alone. - The company estimates the total addressable market for liver-dominant metastatic colorectal cancer receiving third-line treatment represents 6,000 to 10,000 patients annually in the United States. - Primary endpoint results for hepatic progression-free survival are anticipated by mid-2028, with overall survival data expected in late 2028.
- The third annual Bridging the Gaps in Lung Cancer consensus meeting brings together approximately 30 global experts to identify and address unresolved clinical challenges in lung cancer management. - Key knowledge gaps persist in optimal duration of adjuvant targeted therapy, management of patients with complete pathologic response after neoadjuvant chemoimmunotherapy, and treatment guidelines for leptomeningeal disease. - The meeting's unique format focuses exclusively on clinical ambiguity rather than established standards, with consensus recommendations evolving annually as new trial data and biomarker validation studies emerge. - New features include livestreaming and social media integration to broaden reach and demonstrate variability in expert perspectives across different healthcare systems.
- BTX A51, an oral multi-kinase inhibitor targeting CK1α and CDK7/9, demonstrated tolerability and manageable safety in a phase I study of 31 patients with relapsed/refractory AML or MDS. - Three patients (10%) achieved complete remission with incomplete count recovery, with all responders harboring RUNX1 mutations and receiving doses of 11 mg or higher. - The study established 21 mg administered 3 days per week for 28 days as the recommended phase 2 dose, with encouraging activity particularly in RUNX1-mutated patients showing a 30% response rate. - Ex vivo studies demonstrated synergistic effects when BTX A51 was combined with venetoclax and azacitidine, supporting future combination therapy trials.
- Community engagement is fundamental to cancer science, helping researchers address the intersection of cancer, society, and community needs while improving scientific trustworthiness in community settings. - Dr. Kimlin Tam Ashing emphasizes that effective community partnerships enable better science communication, translating complex findings into accessible formats across diverse platforms and languages. - The Cancer Care Equity Act of 2021 in California demonstrates successful community-driven policy change, now allowing Medi-Cal patients with complex cancers to access specialized care, precision medicine, and clinical trials.
- Interim results from the ACROBAT study demonstrate AlloHeme's superior accuracy in detecting post-transplant relapse in AML and MDS patients, with 93% sensitivity and 88% specificity. - The NGS-based assay provides a median 36-day early warning before clinical relapse, potentially offering a crucial window for therapeutic intervention. - AlloHeme significantly outperformed traditional STR testing methods, achieving an area under the curve of 0.90 compared to 0.74 and 0.61 for STR 1% and 5% respectively.
- Lutetium-177 Dotatate (Lutathera) has demonstrated efficacy in treating well-differentiated neuroendocrine tumors (NETs), improving progression-free survival in advanced cases. - Clinical trials, including NETTER-1 and NETTER-2, support the use of Lutetium-177 Dotatate, but researchers are investigating optimal sequencing and combination strategies to enhance outcomes. - Combining Lutetium-177 Dotatate with radiation sensitizers like triapine is being explored in phase 2 trials to improve tumor response and overall efficacy in NET treatment. - Ongoing research focuses on identifying ideal patient candidates for Lutetium-177 Dotatate therapy and minimizing potential toxicities to maximize quality of life and survival.
- Acalabrutinib, umbralisib, and ublituximab (AU2) demonstrated a 100% objective response rate in patients with de novo mantle cell lymphoma (MCL). - The regimen achieved high rates of undetectable minimal residual disease (uMRD), suggesting deep remission in responding patients. - Two-year progression-free survival (PFS) was 63%, and overall survival (OS) was 88%, indicating durable disease control with the AU2 combination. - The study suggests chemotherapy-free approaches are feasible in the frontline setting for MCL, especially for unfit patients.
